Omlyclo (CT-P39), used to treat allergic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic spontaneous urticaria (CSU), becomes the first omalizumab biosimilar approved in the
Celltrion USA s adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition cost prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Respiratory Syncytial Virus (RSV) Therapeutics Market to Grow at CAGR of 13 % through 2031 Owing to Rising Prevalence of RSV Infections and Potential Launch of Novel Therapies bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.
06.05.2024 - - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2024 - - RaniPill HC to be ready for .
According to a recent report from Allied Market Research titled “Arthritic Therapeutic Market by Product Type (Non-steroidal Anti-inflammatory Drugs (NSAIDs), Disease Modified Anti-rheumatoid Drugs (DMARDs), Biologics, and Others) and Application (Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing.